The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Selecting between BTK inhibitors in MCL & addressing resistance to these agents
Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, shares insights on choosing between BTK inhibitors (BTKi) for patients with mantle cell lymphoma (MCL) who progress on initial chemoimmunotherapy and discusses how to approach patients who develop resistance to these agents. Patients with relapsed/refractory (R/R) disease now have a variety of options, including ibrutinib, acalabrutinib, and pirtobrutinib. However, mechanisms of resistance to BTKis are complex and diverse in this disease setting. Prof. Danilov explains that CAR-T cells, such as brexucabtagene autoleucel (brexu-cel) and lisocabtagene maraleucel (liso-cel), and bispecific antibodies, such as glofitamab, may be considered for this patient population. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
